Dotefonium is the anticholinergic, spasmolytic agent.

FLOTRENIZINE, a diarylmethylpiperazine derivative, is an antihistaminic agent.

Nicoclonate is a nicotinic acid derivative. It is an antilipidemic drug.

Silydianin is a flavonolignan from Silymarin, which is the major constituent of milk thistle extract. Silydianin, an active constituent of Silybium marianum, have inhibitory properties against the P2Y12 receptor and block ADP-induced blood platelet activation. Silydianin has antiinflammatory activity, it regulates caspase-3 activation, affects cell membranes and acts as a free radical scavenger. Silydianin non-competitively inhibits the lipoxygenase from soybeans in vitro. It also inhibits the formation of prostaglandins in vitro.

Doxpicomine is the hydrochloride salt of l-3[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine, a derivative of substituted 1,3 dioxanes. Its analgesic effect appears to be mediated centrally through opiate-like receptors. Preclinical animal studies revealed analgesic activity and duration of action of the same order as that of meperidine and codeine when administered subcutaneously and of codeine but of shorter duration when administered orally. The analgesic effects were reversed by naloxone. The drug did not reduce or antagonize the analgesic effect of morphine. Drowsiness is an expected response to effective analgesics. It was the foremost side effect observed but was of short duration and minimal intensity and did not interfere with the postoperative regimen of coughing, deep breathing, and early ambulation. Nausea and vomiting were not reported after doxpicomine.

FLUMEXADOL is a non-opioid analgesic. Its prodrug OXAFLOZANE was used as an antidepressant in France till 2004.

Pipramadol is an analgesic agent. Pipramadol exhibits not only antinociceptive but also central and peripheral antiserotonin properties.

Ragaglitazar (DRF 2725, NNC 61-0029) is phenoxazine analog of phenyl propanoic acid having dual (PPARα and PPARγ) agonist property intended to restore insulin sensitivity and correct diabetic dyslipidemia. PPAR-α is highly expressed in liver and muscle and upon activation leads to decreases in plasma triglycerides and increases in HDL cholesterol levels. PPAR-γ activation leads to enhancement of glucose uptake in skeletal muscles and adipose tissue. Ragaglitazar provided the glycemic control that was comparable with that of pioglitazone and, compared with placebo, provided a significant improvement in the lipid profile.